The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancer.
CXCR4/CXCL12
Chemokines
Immunohistochemistry
Pancreatic ductal adenocarcinoma
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
30
05
2023
accepted:
02
09
2023
medline:
13
9
2023
pubmed:
12
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the main causes of cancer mortality in the world. A characteristic feature of this cancer is that a large part of the tumor volume is composed of a stroma with different cells and factors. Among these, we can highlight the cytokines, which perform their function through binding to their receptors. Given the impact of the CXCR4 receptor in the interactions between tumor cells and their microenvironment and its involvement in important signaling pathways in cancer, it is proposed as a very promising prognostic biomarker and as a goal for new targeted therapies. Numerous studies analyze the expression of CXCR4 but we suggest focusing on the expression of CXCR4 in the stroma. Expression of CXCR4 in specimens from 33 patients with PDAC was evaluated by immunohistochemistry techniques and matched with clinicopathological parameters, overall and disease-free survival rates. The percentage of stroma was lower in non-tumor tissue (32.4 ± 5.2) than in tumor pancreatic tissue (67.4 ± 4.8), P-value = 0.001. The level of CXCR4 expression in stromal cells was diminished in non-tumor tissue (8.7 ± 4.6) and higher in tumor pancreatic tissue (23.5 ± 6.1), P-value = 0.022. No significant differences were identified in total cell count and inflammatory cells between non-tumor tissue and pancreatic tumor tissue. No association was observed between CXCR4 expression and any of the clinical or pathological data, overall and disease-free survival rates. Analyzing exclusively the stroma of tumor samples, the CXCR4 expression was associated with tumor differentiation, P-value = 0.05. In this study, we reflect the importance of CXCR4 expression in the stroma of patients diagnosed with PDAC. Our results revealed a high CXCR4 expression in the tumor stroma, which is related to a poor tumor differentiation. On the contrary, we could not find an association between CXCR4 expression and survival and the rest of the clinicopathological variables. Focusing the study on the CXCR4 expression in the tumor stroma could generate more robust results. Therefore, we consider it key to develop more studies to enlighten the role of this receptor in PDAC and its implication as a possible biomarker.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the main causes of cancer mortality in the world. A characteristic feature of this cancer is that a large part of the tumor volume is composed of a stroma with different cells and factors. Among these, we can highlight the cytokines, which perform their function through binding to their receptors. Given the impact of the CXCR4 receptor in the interactions between tumor cells and their microenvironment and its involvement in important signaling pathways in cancer, it is proposed as a very promising prognostic biomarker and as a goal for new targeted therapies. Numerous studies analyze the expression of CXCR4 but we suggest focusing on the expression of CXCR4 in the stroma.
METHODS
METHODS
Expression of CXCR4 in specimens from 33 patients with PDAC was evaluated by immunohistochemistry techniques and matched with clinicopathological parameters, overall and disease-free survival rates.
RESULTS
RESULTS
The percentage of stroma was lower in non-tumor tissue (32.4 ± 5.2) than in tumor pancreatic tissue (67.4 ± 4.8), P-value = 0.001. The level of CXCR4 expression in stromal cells was diminished in non-tumor tissue (8.7 ± 4.6) and higher in tumor pancreatic tissue (23.5 ± 6.1), P-value = 0.022. No significant differences were identified in total cell count and inflammatory cells between non-tumor tissue and pancreatic tumor tissue. No association was observed between CXCR4 expression and any of the clinical or pathological data, overall and disease-free survival rates. Analyzing exclusively the stroma of tumor samples, the CXCR4 expression was associated with tumor differentiation, P-value = 0.05.
CONCLUSIONS
CONCLUSIONS
In this study, we reflect the importance of CXCR4 expression in the stroma of patients diagnosed with PDAC. Our results revealed a high CXCR4 expression in the tumor stroma, which is related to a poor tumor differentiation. On the contrary, we could not find an association between CXCR4 expression and survival and the rest of the clinicopathological variables. Focusing the study on the CXCR4 expression in the tumor stroma could generate more robust results. Therefore, we consider it key to develop more studies to enlighten the role of this receptor in PDAC and its implication as a possible biomarker.
Identifiants
pubmed: 37697316
doi: 10.1186/s12957-023-03168-6
pii: 10.1186/s12957-023-03168-6
pmc: PMC10496205
doi:
Substances chimiques
CXCR4 protein, human
0
Receptors, CXCR4
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Surg Oncol. 2011 Aug 1;104(2):140-5
pubmed: 21520098
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970
pubmed: 33127761
Immunol Lett. 2020 Jan;217:91-115
pubmed: 31747563
Cancer Res. 2004 Nov 15;64(22):8420-7
pubmed: 15548713
Stem Cells Dev. 2012 Feb 10;21(3):476-86
pubmed: 21513440
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Oncol Rep. 2006 Dec;16(6):1159-64
pubmed: 17089032
Transl Lung Cancer Res. 2021 Apr;10(4):1889-1916
pubmed: 34012800
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Molecules. 2022 Mar 22;27(7):
pubmed: 35408440
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502
pubmed: 34002083
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Cancers (Basel). 2019 Aug 08;11(8):
pubmed: 31398893
Oncol Lett. 2018 Feb;15(2):1771-1776
pubmed: 29434873
Cytokine Growth Factor Rev. 2012 Dec;23(6):343-56
pubmed: 22749856
Glia. 2014 Jul;62(7):1015-23
pubmed: 24715652
J Surg Res. 2011 Nov;171(1):143-50
pubmed: 20462600
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
pubmed: 14595012
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
Front Oncol. 2021 Oct 14;11:692788
pubmed: 34722241
Int J Oncol. 2012 Oct;41(4):1314-24
pubmed: 22824809
Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):641-646
pubmed: 28276831
BMC Cancer. 2014 Sep 21;14:687
pubmed: 25240521
Int J Cancer. 2018 Sep 1;143(5):1017-1028
pubmed: 29417588
Toxicology. 2013 Dec 15;314(2-3):209-20
pubmed: 24157575
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Oncogene. 2003 Nov 6;22(50):8093-101
pubmed: 14603250
Trends Biotechnol. 1996 Feb;14(2):46-51
pubmed: 8746116
Cancers (Basel). 2021 Dec 24;14(1):
pubmed: 35008248
J Transl Med. 2012 Apr 02;10:68
pubmed: 22472349
Gut. 2015 Sep;64(9):1476-84
pubmed: 25994217
FASEB J. 2004 Aug;18(11):1240-2
pubmed: 15180966